Tesamorelin

Both are GHRH analogues that act on the same pituitary receptor. Tesamorelin is cleared within minutes and, in its labeled use, is injected daily. CJC-1295 with DAC binds to albumin in the blood and has a half-life of about a week. Community guides often say CJC-1295 with DAC causes a constant 'bleed' of GH, but in a 2006 study of healthy men, GH pulses kept their normal frequency and size one week after a dose; baseline GH between pulses rose about 7.5-fold. As of October 2026, tesamorelin is an FDA-approved prescription medicine (Egrifta) for HIV-associated lipodystrophy, while CJC-1295 isn't approved anywhere.

As of October 2026, its FDA approval covers only adults with HIV-associated lipodystrophy, and the label says it isn't for weight loss. Other uses are off-label, and human data outside that group are thin. The best-known example is a 2012 trial in 152 adults aged 55-87, which found better executive function scores after 20 weeks of 1 mg daily; it also found higher fasting insulin in the participants with mild cognitive impairment. No trial has tested tesamorelin for general fat loss in people without HIV. Questions about the prescription medicine belong with a healthcare professional.

'GH gut' is a bodybuilding term for a distended abdomen that users blame on years of high-dose growth hormone. We found no study that measured it with tesamorelin. In the Phase 3 trials, visceral fat fell over 26 weeks and came back after stopping. Those trials also found IGF-1 above the normal range in 47% of participants at 26 weeks, so the common claim that a GHRH analogue can't cause effects of excess GH isn't settled.

In the Phase 3 trials, visceral fat was measured by CT scan at 26 weeks, when it was 14-18% lower than at baseline (vs -2% to +2% on placebo). IGF-1 was above the normal range in some participants by 13 weeks. Users on peptide forums describe earlier changes, such as water retention in the first few weeks; these are self-reports that no trial measured.